

# Lee Ratner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8495209/publications.pdf>

Version: 2024-02-01

202  
papers

13,542  
citations

34105

52  
h-index

26613

107  
g-index

204  
all docs

204  
docs citations

204  
times ranked

9689  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study. <i>Oncologist</i> , 2022, 27, 623-e624.	3.7	2
2	Epigenetic Regulation of Human T-Cell Leukemia Virus Gene Expression. <i>Microorganisms</i> , 2022, 10, 84.	3.6	3
3	Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. <i>Journal of Virology</i> , 2022, 96, e0005722.	3.4	14
4	The Past, Present, and Future of a Human T-Cell Leukemia Virus Type 1 Vaccine. <i>Frontiers in Microbiology</i> , 2022, 13, .	3.5	8
5	Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. <i>Haematologica</i> , 2021, 106, 730-735.	3.5	8
6	Epigenomic regulation of human T-cell leukemia virus by chromatin-insulator CTCF. <i>PLoS Pathogens</i> , 2021, 17, e1009577.	4.7	12
7	Targeting NF- $\kappa$ B with Nanotherapy in a Mouse Model of Adult T-Cell Leukemia/Lymphoma. <i>Nanomaterials</i> , 2021, 11, 1582.	4.1	8
8	Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases. <i>Molecular Cancer</i> , 2021, 20, 86.	19.2	7
9	Molecular biology of human T cell leukemia virus. <i>Seminars in Diagnostic Pathology</i> , 2020, 37, 104-109.	1.5	15
10	Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma. <i>Retrovirology</i> , 2020, 17, 27.	2.0	8
11	Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial). <i>Blood</i> , 2020, 136, 1284-1297.	1.4	39
12	Predicting the future: adult T-cell leukemia. <i>Blood</i> , 2020, 135, 2013-2014.	1.4	1
13	The Dual-Specificity Kinase DYRK1A Modulates the Levels of Cyclin L2 To Control HIV Replication in Macrophages. <i>Journal of Virology</i> , 2020, 94, .	3.4	12
14	The human T-cell leukemia virus type-1 tax oncoprotein dissociates NF- $\kappa$ B p65RelA-Stathmin complexes and causes catastrophic mitotic spindle damage and genomic instability. <i>Virology</i> , 2019, 535, 83-101.	2.4	5
15	Biomarkers and Preclinical Models for Adult T-Cell Leukemia-Lymphoma Treatment. <i>Frontiers in Microbiology</i> , 2019, 10, 2109.	3.5	1
16	Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade. <i>Blood</i> , 2019, 134, 1406-1414.	1.4	80
17	Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. <i>Journal of Clinical Oncology</i> , 2019, 37, 677-687.	1.6	162
18	Dynamic host immune response in virus-associated cancers. <i>Communications Biology</i> , 2019, 2, 109.	4.4	34

#	ARTICLE	IF	CITATIONS
19	HTLV-1 Tax-1 interacts with SNX27 to regulate cellular localization of the HTLV-1 receptor molecule, GLUT1. PLoS ONE, 2019, 14, e0214059.	2.5	18
20	V1 and V2 Domains of HIV Envelope Contribute to CCR5 Antagonist Resistance. Journal of Virology, 2019, 93, .	3.4	5
21	AIDS-Related Kaposi Sarcoma, Version 2.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 171-189.	4.9	35
22	HTLV-1 CTCF-binding site is dispensable for in vitro immortalization and persistent infection in vivo. Retrovirology, 2019, 16, 44.	2.0	20
23	HTLV-1 viral oncogene HBZ drives bone destruction in adult T cell leukemia. JCI Insight, 2019, 4, .	5.0	12
24	The human T-cell leukemia virus type-1 p30II protein activates p53 and induces the TIGAR and suppresses oncogene-induced oxidative stress during viral carcinogenesis. Virology, 2018, 518, 103-115.	2.4	17
25	Safety and Preliminary Efficacy of Vorinostat WithÂR-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 180-190.e2.	0.4	11
26	Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma. Aids, 2018, 32, 605-611.	2.2	24
27	An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia. Journal of Biological Chemistry, 2018, 293, 6844-6858.	3.4	21
28	Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency. MBio, 2018, 9, .	4.1	12
29	North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood, 2018, 132, 1507-1518.	1.4	63
30	Rapid Progression of Adult T-Cell Leukemiaâ€“Lymphoma after PD-1 Inhibitor Therapy. New England Journal of Medicine, 2018, 378, 1947-1948.	27.0	185
31	PD-1 Inhibitor Therapy in Adult T-Cell Leukemiaâ€“Lymphoma. New England Journal of Medicine, 2018, 379, 695-697.	27.0	37
32	Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 986-1017.	4.9	64
33	The TP53-Induced Glycolysis and Apoptosis Regulator mediates cooperation between HTLV-1 p30II and the retroviral oncoproteins Tax and HBZ and is highly expressed in an in vivo xenograft model of HTLV-1-induced lymphoma. Virology, 2018, 520, 39-58.	2.4	15
34	PDZ domain-binding motif of Tax sustains T-cell proliferation in HTLV-1-infected humanized mice. PLoS Pathogens, 2018, 14, e1006933.	4.7	22
35	Role of Wild-type and Recombinant Human T-cell Leukemia Viruses in Lymphoproliferative Disease in Humanized NSG Mice. Comparative Medicine, 2018, 68, 4-14.	1.0	11
36	High frequency of identical clonal immunoglobulin DNA in pre-treatment tumor and plasma from untreated patients with HIV-associated lymphoma: prospective multicenter trial of the AIDS malignancies consortium (AMC 064). Leukemia and Lymphoma, 2017, 58, 2939-2942.	1.3	2

#	ARTICLE	IF	CITATIONS
37	Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 727-733.	1.6	64
38	Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. <i>Scientific Reports</i> , 2017, 7, 7456.	3.3	32
39	Adult T-Cell Leukemia/Lymphoma. <i>Journal of Oncology Practice</i> , 2017, 13, 487-492.	2.5	48
40	HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice. <i>Oncotarget</i> , 2017, 8, 69250-69263.	1.8	16
41	Novel interactions between the HTLV antisense proteins HBZ and APH-2 and the NFAR protein family: Implications for the HTLV lifecycles. <i>Virology</i> , 2016, 494, 129-142.	2.4	10
42	Evolution of coreceptor utilization to escape CCR5 antagonist therapy. <i>Virology</i> , 2016, 494, 198-214.	2.4	8
43	Human T-cell leukemia virus-associated malignancy. <i>Current Opinion in Virology</i> , 2016, 20, 40-46.	5.4	39
44	Mutation of epigenetic regulators TET2 and MLL3 in patients with HTLV-I-induced acute adult T-cell leukemia. <i>Molecular Cancer</i> , 2016, 15, 15.	19.2	30
45	Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. <i>Leukemia and Lymphoma</i> , 2016, 57, 1731-1734.	1.3	24
46	Inducible nitric oxide synthase mediates DNA double strand breaks in Human T-Cell Leukemia Virus Type 1-induced leukemia/lymphoma. <i>Retrovirology</i> , 2015, 12, 71.	2.0	25
47	AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. <i>Blood</i> , 2015, 126, 160-166.	1.4	82
48	Acetylation of the c-MYC oncoprotein is required for cooperation with the HTLV-1 p30 II accessory protein and the induction of oncogenic cellular transformation by p30 II /c-MYC. <i>Virology</i> , 2015, 476, 271-288.	2.4	14
49	Cyclin L2 Is a Critical HIV Dependency Factor in Macrophages that Controls SAMHD1 Abundance. <i>Cell Host and Microbe</i> , 2015, 17, 98-106.	11.0	46
50	Human T-Cell Leukemia Virus Type 1 (HTLV-1) Tax Requires CADM1/TSLC1 for Inactivation of the NF- $\kappa$ B Inhibitor A20 and Constitutive NF- $\kappa$ B Signaling. <i>PLoS Pathogens</i> , 2015, 11, e1004721.	4.7	44
51	How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?. <i>Current Opinion in Virology</i> , 2015, 14, 93-100.	5.4	78
52	Akt Pathway Activation by Human T-cell Leukemia Virus Type 1 Tax Oncoprotein. <i>Journal of Biological Chemistry</i> , 2015, 290, 26270-26281.	3.4	23
53	AMC-085: A Pilot Trial of AVD and Brentuximab Vedotin in the Upfront Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma. A Trial of the AIDS Malignancy Consortium. <i>Blood</i> , 2015, 126, 1526-1526.	1.4	2
54	A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061. <i>Cancer</i> , 2014, 120, 1194-1202.	4.1	26

#	ARTICLE	IF	CITATIONS
55	HIV-2 Vpx Protein Interacts with Interferon Regulatory Factor 5 (IRF5) and Inhibits Its Function. <i>Journal of Biological Chemistry</i> , 2014, 289, 9146-9157.	3.4	15
56	IL-15 deficient Tax mice reveal a role for IL-1 $\beta$ in tumor immunity. <i>Retrovirology</i> , 2014, 11, O11.	2.0	1
57	IL-15 Deficient Tax Mice Reveal a Role for IL-1 $\beta$ in Tumor Immunity. <i>PLoS ONE</i> , 2014, 9, e85028.	2.5	10
58	Cytolytic Nanoparticles Attenuate HIV-1 Infectivity. <i>Antiviral Therapy</i> , 2013, 18, 95-103.	1.0	92
59	Mechanisms of Nanoparticle-Mediated siRNA Transfection by Melittin-Derived Peptides. <i>ACS Nano</i> , 2013, 7, 8605-8615.	14.6	79
60	Alpha Interferon Restricts Human T-Lymphotropic Virus Type 1 and 2 <i>De Novo</i> Infection through PKR Activation. <i>Journal of Virology</i> , 2013, 87, 13386-13396.	3.4	27
61	Pegylated Liposomal Doxorubicin, Rituximab, Cyclophosphamide, Vincristine, and Prednisone in AIDS-Related Lymphoma: AIDS Malignancy Consortium Study 047. <i>Journal of Clinical Oncology</i> , 2013, 31, 58-64.	1.6	31
62	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. <i>Blood</i> , 2013, 122, 3251-3262.	1.4	156
63	Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. <i>Leukemia and Lymphoma</i> , 2012, 53, 2383-2389.	1.3	23
64	Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis. <i>Retrovirology</i> , 2012, 9, 114.	2.0	28
65	Vpx is Critical for SIV <sub>mac</sub> infection of pigtail macaques. <i>Retrovirology</i> , 2012, 9, 32.	2.0	33
66	The Smac mimetic RMT5265.2HCL induces apoptosis in EBV and HTLV-I associated lymphoma cells by inhibiting XIAP and promoting the mitochondrial release of cytochrome C and Smac. <i>Leukemia Research</i> , 2012, 36, 784-790.	0.8	7
67	HIV-2 viral protein X (Vpx) ubiquitination is dispensable for ubiquitin ligase interaction and effects on macrophage infection. <i>Virology</i> , 2012, 427, 67-75.	2.4	4
68	Integrase Inhibitors Effective against Human T-Cell Leukemia Virus Type 1. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2011-2017.	3.2	50
69	JAK blockade and HTLV. <i>Blood</i> , 2011, 117, 1771-1772.	1.4	6
70	The HTLV-1 hbz antisense gene indirectly promotes tax expression via down-regulation of p30II mRNA. <i>Virology</i> , 2011, 410, 307-315.	2.4	26
71	Post-formulation peptide drug loading of nanostructures for metered control of NF- $\kappa$ B signaling. <i>Biomaterials</i> , 2011, 32, 231-238.	11.4	18
72	Molecular Determinants of Human T-lymphotropic Virus Type 1 Transmission and Spread. <i>Viruses</i> , 2011, 3, 1131-1165.	3.3	40

#	ARTICLE	IF	CITATIONS
73	Targeting HTLV-1 Activation of NF $\kappa$ B in Mouse Models and ATLL Patients. <i>Viruses</i> , 2011, 3, 886-900.	3.3	24
74	Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2010, 115, 3008-3016.	1.4	254
75	HIV-1 determinants of thrombocytopenia at the stage of CD34+ progenitor cell differentiation in vivo lie in the viral envelope gp120 V3 loop region. <i>Virology</i> , 2010, 401, 131-136.	2.4	7
76	Role of Abl Kinase and the Wave2 Signaling Complex in HIV-1 Entry at a Post-Hemifusion Step. <i>PLoS Pathogens</i> , 2010, 6, e1000956.	4.7	102
77	The ARF Tumor Suppressor Regulates Bone Remodeling and Osteosarcoma Development in Mice. <i>PLoS ONE</i> , 2010, 5, e15755.	2.5	20
78	Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting. <i>Journal of Clinical Oncology</i> , 2009, 27, 453-459.	1.6	485
79	Suppression of Human T-cell Leukemia Virus I Gene Expression by Pokeweed Antiviral Protein. <i>Journal of Biological Chemistry</i> , 2009, 284, 31453-31462.	3.4	45
80	Molecular and Clinical Assessment in the Treatment of AIDS Kaposi Sarcoma with Valproic Acid. <i>Clinical Infectious Diseases</i> , 2009, 49, 1946-1949.	5.8	24
81	Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail. <i>Virology</i> , 2009, 384, 233-241.	2.4	17
82	Acetylation of the human T-cell leukemia virus type 1 Tax oncoprotein by p300 promotes activation of the NF $\kappa$ B pathway. <i>Virology</i> , 2009, 386, 68-78.	2.4	45
83	Bioluminescence imaging of myeloperoxidase activity in vivo. <i>Nature Medicine</i> , 2009, 15, 455-461.	30.7	291
84	T-cell activation promotes tumorigenesis in inflammation-associated cancer. <i>Retrovirology</i> , 2009, 6, 116.	2.0	32
85	Imaging spontaneous tumorigenesis: inflammation precedes development of peripheral NK tumors. <i>Blood</i> , 2009, 113, 1493-1500.	1.4	34
86	Human T Cell Leukemia Virus Reactivation with Progression of Adult T-Cell Leukemia-Lymphoma. <i>PLoS ONE</i> , 2009, 4, e4420.	2.5	40
87	Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. <i>Virology</i> , 2008, 374, 210-216.	2.4	26
88	Modulation of $\beta$ -Catenin and E-Cadherin Interaction by Vpu Increases Human Immunodeficiency Virus Type 1 Particle Release. <i>Journal of Virology</i> , 2008, 82, 3932-3938.	3.4	12
89	Hsp40 Facilitates Nuclear Import of the Human Immunodeficiency Virus Type 2 Vpx-Mediated Preintegration Complex. <i>Journal of Virology</i> , 2008, 82, 1229-1237.	3.4	48
90	Induction of the G $\alpha$ Signaling Cascade by the Human Immunodeficiency Virus Envelope Is Required for Virus Entry. <i>Journal of Virology</i> , 2008, 82, 9191-9205.	3.4	69

#	ARTICLE	IF	CITATIONS
91	IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. <i>Blood</i> , 2007, 109, 3060-3068.	1.4	66
92	HTLV-1, Cytokines, and Cancer. , 2007, , 27-51.		0
93	Human T-lymphotropic virus type-1 p30 alters cell cycle G2 regulation of T lymphocytes to enhance cell survival. <i>Retrovirology</i> , 2007, 4, 49.	2.0	36
94	Effect of treatment of <i>Strongyloides</i> infection on HTLV-1 expression in a patient with adult T-cell leukemia. <i>American Journal of Hematology</i> , 2007, 82, 929-931.	4.1	17
95	Antiviral activity of a Rac GEF inhibitor characterized with a sensitive HIV/SIV fusion assay. <i>Virology</i> , 2007, 368, 1-6.	2.4	18
96	Characterization of replication defects induced by mutations in the basic domain and C-terminus of HIV-1 matrix. <i>Virology</i> , 2007, 369, 47-54.	2.4	20
97	Antiviral and Immunomodulatory Treatment for AIDS-Related Primary Central Nervous System Lymphoma: AIDS Malignancies Consortium Pilot Study 019. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 399-402.	1.4	37
98	Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells. <i>Virology</i> , 2006, 346, 118-126.	2.4	36
99	Analysis of HIV-2 Vpx by modeling and insertional mutagenesis. <i>Virology</i> , 2006, 348, 165-174.	2.4	13
100	Histone acetyltransferase (HAT) activity of p300 modulates human T lymphotropic virus type 1 p30II-mediated repression of LTR transcriptional activity. <i>Virology</i> , 2006, 354, 225-239.	2.4	21
101	Foxp3 Represses Retroviral Transcription by Targeting Both NF- $\kappa$ B and CREB Pathways. <i>PLoS Pathogens</i> , 2006, 2, e33.	4.7	72
102	The role of NF- $\kappa$ B-1 and NF- $\kappa$ B-2-mediated resistance to apoptosis in lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 9220-9225.	7.1	104
103	Human T-Lymphotropic Virus Type 1 Mitochondrion-Localizing Protein p13 II Is Required for Viral Infectivity In Vivo. <i>Journal of Virology</i> , 2006, 80, 3469-3476.	3.4	51
104	Human T cell lymphotropic virus-associated leukemia/lymphoma. <i>Current Opinion in Oncology</i> , 2005, 17, 469-473.	2.4	19
105	In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations. <i>Blood</i> , 2005, 106, 3602-3608.	1.4	10
106	HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. <i>Blood</i> , 2005, 106, 4294-4302.	1.4	66
107	Pathogenesis and Treatment of Human T-Cell Leukemia Virus Infection. <i>Immunologic Research</i> , 2005, 32, 217-224.	2.9	9
108	Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. <i>Oncogene</i> , 2005, 24, 6005-6015.	5.9	65

#	ARTICLE	IF	CITATIONS
109	Cholesterol Dependence of HTLV-I Infection. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 43-50.	1.1	27
110	Accumulation of NFκB1 (p105) and NFκB2 (p100) Is Essential for Apoptosis Induced by Proteasome Inhibition in a Lymphoma Model. <i>Blood</i> , 2005, 106, 2607-2607.	1.4	0
111	Anti-Vpr Activity of a Yeast Chaperone Protein. <i>Journal of Virology</i> , 2004, 78, 11016-11029.	3.4	26
112	Role of Human Immunodeficiency Virus Type 1 Matrix Phosphorylation in an Early Postentry Step of Virus Replication. <i>Journal of Virology</i> , 2004, 78, 2319-2326.	3.4	33
113	Human T-Cell Lymphotropic Virus Type 1 Open Reading Frame II-Encoded p30 II Is Required for In Vivo Replication: Evidence of In Vivo Reversion. <i>Journal of Virology</i> , 2004, 78, 3837-3845.	3.4	76
114	Substitution of HIV Type 1 Nef with HTLV-1 p12. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 938-943.	1.1	8
115	Enhanced tumorigenesis in HTLV-1 Tax-transgenic mice deficient in interferon-gamma. <i>Blood</i> , 2004, 104, 3305-3311.	1.4	52
116	Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. <i>Blood</i> , 2004, 104, 802-809.	1.4	51
117	Adult T cell leukemia lymphoma. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 2852.	3.0	28
118	Identification of the nuclear localization signal of human immunodeficiency virus type 2 Vpx. <i>Virology</i> , 2003, 311, 7-15.	2.4	27
119	AlphaInterferon Inhibits Human T-Cell Leukemia Virus Type 1 Assembly by Preventing Gag Interaction with Rafts. <i>Journal of Virology</i> , 2003, 77, 13389-13395.	3.4	52
120	Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients. <i>Current Opinion in Oncology</i> , 2002, 14, 538-542.	2.4	22
121	Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 153-159.	1.6	134
122	Engraftment and tumorigenesis of HTLV-1 transformed T cell lines in SCID/bg and NOD/SCID mice. <i>Leukemia Research</i> , 2002, 26, 561-567.	0.8	35
123	Interaction of HIV-1 Gag and Membranes in a Cell-Free System. <i>Virology</i> , 2002, 302, 164-173.	2.4	7
124	Association of Primate T-Cell Lymphotropic Virus Infection of Pig-Tailed Macaques with High Mortality. <i>Virology</i> , 2002, 304, 364-378.	2.4	18
125	HIV Type 2 Vpx Interaction with Gag and Incorporation into Virus-Like Particles. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 105-111.	1.1	16
126	Chemotherapy for Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma in Combination With Highly Active Antiretroviral Therapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 2171-2178.	1.6	264



#	ARTICLE	IF	CITATIONS
127	Title is missing!. Applied Immunohistochemistry & Molecular Morphology, 2001, 9, 371-379.	2.0	2
128	The contribution of NF- $\kappa$ B activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood, 2001, 98, 1200-1208.	1.4	88
129	Tracking the Assembly Pathway of Human Immunodeficiency Virus Type 1 Gag Deletion Mutants by Immunogold Labeling. Applied Immunohistochemistry and Molecular Morphology, 2001, 9, 371-379.	1.2	4
130	A Novel Inducible Expression System to Study Transdominant Mutants of HIV-1 Vpr. Virology, 2001, 287, 133-142.	2.4	19
131	Analysis of p53 Inactivation in a Human T-Cell Leukemia Virus Type 1 Tax Transgenic Mouse Model. Journal of Virology, 2001, 75, 2185-2193.	3.4	32
132	Viral Protein U (Vpu)-Mediated Enhancement of Human Immunodeficiency Virus Type 1 Particle Release Depends on the Rate of Cellular Proliferation. Journal of Virology, 2001, 75, 6714-6718.	3.4	26
133	Characterization of Envelope Glycoprotein Mutants for Human T-Cell Leukemia Virus Type 1 Infectivity and immortalization. Journal of Virology, 2001, 75, 9553-9559.	3.4	12
134	Sensitivity of Human Immunodeficiency Virus Type 1 to Fusion Inhibitors Targeted to the gp41 First Heptad Repeat Involves Distinct Regions of gp41 and Is Consistently Modulated by gp120 Interactions with the Coreceptor. Journal of Virology, 2001, 75, 8605-8614.	3.4	184
135	Evidence for Common Structural Determinants of Human Immunodeficiency Virus Type 1 Coreceptor Activity Provided through Functional Analysis of CCR5/CXCR4 Chimeric Coreceptors. Journal of Virology, 2001, 75, 11503-11514.	3.4	29
136	Chemotherapy Consisting of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine With Granulocyte- $\kappa$ Colony-Stimulating Factor in HIV-Infected Patients With Newly Diagnosed Hodgkin's Disease: A Prospective, Multi-institutional AIDS Clinical Trials Group Study (ACTG 149). Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 24, 444-450.	2.1	33
137	Multidrug resistance transporters and modulation. Current Opinion in Oncology, 2000, 12, 450-458.	2.4	333
138	Rapid phenotypic drug susceptibility assay for HIV-1 with a CCR5 expressing indicator cell line. Journal of Virological Methods, 2000, 85, 151-161.	2.1	27
139	The HTLV Receptor Is a Widely Expressed Protein. Virology, 2000, 268, 41-48.	2.4	53
140	Productive Infection of CD34+-Cell-Derived Megakaryocytes by X4 and R5 HIV-1 Isolates. Virology, 2000, 269, 78-85.	2.4	29
141	The N-Terminal Matrix Domain of HIV-1 Gag Is Sufficient but Not Necessary for Viral Protein U-Mediated Enhancement of Particle Release through a Membrane-Targeting Mechanism. Virology, 2000, 269, 305-312.	2.4	15
142	Studies of the Immortalizing Activity of HTLV Type 1 Tax, Using an Infectious Molecular Clone and Transgenic Mice. AIDS Research and Human Retroviruses, 2000, 16, 1647-1651.	1.1	16
143	Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120. Journal of Virology, 2000, 74, 8358-8367.	3.4	714
144	Human T-Lymphotropic Virus Type 1 Open Reading Frame I p12I Is Required for Efficient Viral Infectivity in Primary Lymphocytes. Journal of Virology, 2000, 74, 9828-9835.	3.4	95

#	ARTICLE	IF	CITATIONS
145	Chemotherapy Consisting of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine With Granulocyte Colony-Stimulating Factor in HIV-Infected Patients With Newly Diagnosed Hodgkin's Disease: A Prospective, Multi-institutional AIDS Clinical Trials Group Study (ACTG 149). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 444-450.	2.1	94
146	Phosphorylation of Human Immunodeficiency Virus Type 1 Vpr Regulates Cell Cycle Arrest. <i>Journal of Virology</i> , 2000, 74, 6520-6527.	3.4	53
147	Interaction of Human Immunodeficiency Virus Type 2 Vpx and Invariant Chain. <i>Journal of Virology</i> , 2000, 74, 6168-6172.	3.4	13
148	Functional Role of pX Open Reading Frame II of Human T-Lymphotropic Virus Type 1 in Maintenance of Viral Loads In Vivo. <i>Journal of Virology</i> , 2000, 74, 1094-1100.	3.4	119
149	The C-Terminal Proline-Rich Tail of Human Immunodeficiency Virus Type 2 Vpx Is Necessary for Nuclear Localization of the Viral Preintegration Complex in Nondividing Cells. <i>Journal of Virology</i> , 2000, 74, 6162-6167.	3.4	65
150	Immortalization of T Lymphocytes by Human T-Cell Leukemia Virus Type 1 Is Independent of the Tax-CBP/p300 Interaction. <i>Journal of Virology</i> , 2000, 74, 11988-11992.	3.4	19
151	Immortalization of CD4 <sup>+</sup> and CD8 <sup>+</sup> T Lymphocytes by Human T-Cell Leukemia Virus Type 1 Tax Mutants Expressed in a Functional Molecular Clone. <i>Journal of Virology</i> , 1999, 73, 4856-4865.	3.4	197
152	Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. <i>Nature Medicine</i> , 1999, 5, 29-33.	30.7	226
153	Relationship between Productive HIV-1 Infection of Macrophages and CCR5 Utilization. <i>Virology</i> , 1999, 264, 278-288.	2.4	20
154	Analysis of the Critical Domain in the V3 Loop of Human Immunodeficiency Virus Type 1 gp120 Involved in CCR5 Utilization. <i>Journal of Virology</i> , 1999, 73, 8216-8226.	3.4	112
155	Proliferation Response to Interleukin-2 and Jak/Stat Activation of T Cells Immortalized by Human T-Cell Lymphotropic Virus Type 1 Is Independent of Open Reading Frame I Expression. <i>Journal of Virology</i> , 1999, 73, 9642-9649.	3.4	39
156	Distinct Human Immunodeficiency Virus Strains in the Bone Marrow Are Associated with the Development of Thrombocytopenia. <i>Journal of Virology</i> , 1999, 73, 3497-3504.	3.4	12
157	Arginine Residues in the C-terminus of HIV-1 Vpr Are Important for Nuclear Localization and Cell Cycle Arrest. <i>Virology</i> , 1998, 242, 414-424.	2.4	61
158	Quantification of human T-cell lymphotropic virus type 1 proviral load by quantitative competitive polymerase chain reaction. <i>Journal of Virological Methods</i> , 1998, 75, 123-140.	2.1	33
159	Viral Protein R Regulates Docking of the HIV-1 Preintegration Complex to the Nuclear Pore Complex. <i>Journal of Biological Chemistry</i> , 1998, 273, 13347-13352.	3.4	164
160	Selective Ablation of Human T-Cell Lymphotropic Virus Type 1 p12I Reduces Viral Infectivity In Vivo. <i>Blood</i> , 1998, 91, 4701-4707.	1.4	151
161	Human T-Cell Leukemia Virus Type 1 pX-I and pX-II Open Reading Frames Are Dispensable for the Immortalization of Primary Lymphocytes. <i>Journal of Virology</i> , 1998, 72, 4458-4462.	3.4	88
162	Particle Size Determinants in the Human Immunodeficiency Virus Type 1 Gag Protein. <i>Journal of Virology</i> , 1998, 72, 4667-4677.	3.4	51

#	ARTICLE	IF	CITATIONS
163	Human Immunodeficiency Virus Type 2 Vpx-Gag Interaction. <i>Journal of Virology</i> , 1998, 72, 5271-5275.	3.4	25
164	Selective Ablation of Human T-Cell Lymphotropic Virus Type 1 p12I Reduces Viral Infectivity In Vivo. <i>Blood</i> , 1998, 91, 4701-4707.	1.4	52
165	The Tax Protein of Human T-cell Leukemia Virus Type 1 Mediates the Transactivation of the c-sis/Platelet-derived Growth Factor-B Promoter through Interactions with the Zinc Finger Transcription Factors Sp1 and NGFI-A/Egr-1. <i>Journal of Biological Chemistry</i> , 1997, 272, 27411-27421.	3.4	44
166	The use of new antiretroviral therapy in combination with chemotherapy. <i>Current Opinion in Oncology</i> , 1997, 9, 455-464.	2.4	18
167	Cytokine Expression and Tumorigenicity of Large Granular Lymphocytic Leukemia Cells From Mice Transgenic for the tax Gene of Human T-Cell Leukemia Virus Type I. <i>Blood</i> , 1997, 90, 783-794.	1.4	36
168	Cytokine Expression and Tumorigenicity of Large Granular Lymphocytic Leukemia Cells From Mice Transgenic for the tax Gene of Human T-Cell Leukemia Virus Type I. <i>Blood</i> , 1997, 90, 783-794.	1.4	2
169	c- / Promoter Transactivation by the Tax Protein of Human T-cell Leukemia Virus Type 1. <i>Journal of Biological Chemistry</i> , 1996, 271, 14584-14590.	3.4	22
170	<i>Virology. Aids</i> , 1996, 10, S1-2.	2.2	12
171	Sequence Heterogeneity of Nef Transcripts in HIV-1-Infected Subjects at Different Stages of Disease. <i>Virology</i> , 1996, 223, 245-250.	2.4	15
172	Genetic determinants controlling HIV-1 tropism for CD4 <sup>+</sup> /GalCer <sup>+</sup> human intestinal epithelial cells. <i>Journal of Computer - Aided Molecular Design</i> , 1996, 5, 161-168.	1.0	5
173	Transgenic Mouse Models for HTLV-I Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1996, 13, S162-S169.	0.3	15
174	Nef and LTR Sequence Variation from Sequentially Derived Human Immunodeficiency Virus Type 1 Isolates. <i>Virology</i> , 1995, 208, 388-398.	2.4	36
175	Structure and Expression of the Human T-Cell Leukemia Virus Type 1 Envelope Protein. <i>Virology</i> , 1994, 199, 331-338.	2.4	20
176	HIV-2 Viral Protein X Association with the Gag p27 Capsid Protein. <i>Virology</i> , 1994, 199, 453-457.	2.4	33
177	Construction and Characterization of Infectious Human T-Cell Leukemia Virus Type 1 Molecular Clones. <i>Virology</i> , 1994, 204, 656-664.	2.4	127
178	Myristoylation-Enhanced Binding of the HIV-1 Net Protein to T Cell Skeletal Matrix. <i>Virology</i> , 1993, 197, 420-425.	2.4	86
179	Identification of HIV1 Determinants for T Lymphoid Cell Line Infection. <i>Virology</i> , 1993, 197, 817-824.	2.4	33
180	HIV life cycle and genetic approaches. <i>Journal of Computer - Aided Molecular Design</i> , 1993, 1, 3-22.	1.0	12

#	ARTICLE	IF	CITATIONS
181	Mechanism of Action of N-Butyl Deoxyjirimycin in Inhibiting HIV-1 Infection and Activity in Combination with Nucleoside Analogs. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 291-297.	1.1	30
182	Evolution of Sequence Divergence among Human Immunodeficiency Virus Type 1 Isolates Derived from a Blood Donor and a Recipient. <i>Pediatric Research</i> , 1993, 33, 36-42.	2.3	20
183	Alterations in Spliced and Unspliced HIV-1-Specific RNA Detection in Peripheral Blood Mononuclear Cells of Individuals with Varying CD4-Positive Lymphocyte Counts. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 1257-1263.	1.1	18
184	Structure-function relationships of the HIV-1 envelope V3 loop tropism determinant. <i>Aids</i> , 1993, 7, 639-646.	2.2	35
185	Molecular biology and pathogenesis of HIV infection. <i>Current Opinion in Infectious Diseases</i> , 1993, 6, 181-190.	3.1	6
186	Glucosidase Inhibitors for Treatment of HIV-1 Infection. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 165-173.	1.1	66
187	Biology and molecular biology of human immunodeficiency virus. <i>Pediatric Infectious Disease Journal</i> , 1992, 11, 390-400.	2.0	9
188	Inhibition of HIV and SIV infectivity by blockade of $\beta$ -glucosidase activity. <i>Virology</i> , 1991, 181, 180-192.	2.4	109
189	Nucleotide Sequence Analysis of Isolates of Human T-Lymphotropic Virus Type 1 of Diverse Geographical Origins. <i>AIDS Research and Human Retroviruses</i> , 1991, 7, 923-941.	1.1	123
190	Attenuation of HIV-1 Infectivity by an Inhibitor of Oligosaccharide Processing. <i>AIDS Research and Human Retroviruses</i> , 1990, 6, 785-794.	1.1	50
191	Specificity of Polymerase Chain Amplification Reactions for Human Immunodeficiency Virus Type 1 DNA Sequences. <i>AIDS Research and Human Retroviruses</i> , 1989, 5, 87-95.	1.1	24
192	Regulation of expression of the c-sis proto-oncogene. <i>Nucleic Acids Research</i> , 1989, 17, 4101-4115.	14.5	40
193	Analysis of the function of viral protein X (VPX) of HIV-2. <i>Virology</i> , 1989, 173, 624-630.	2.4	53
194	Leukemias Associated with Human T-Cell Lymphotropic Virus Type I in a Non-Endemic Region. <i>Medicine (United States)</i> , 1988, 67, 401.	1.0	66
195	Sequences of the 5' portion of the human c-sis gene: characterization of the transcriptional promoter and regulation of expression of the protein product by 5' untranslated mRNA sequences. <i>Nucleic Acids Research</i> , 1987, 15, 6017-6036.	14.5	84
196	Complete Nucleotide Sequences of Functional Clones of the AIDS Virus. <i>AIDS Research and Human Retroviruses</i> , 1987, 3, 57-69.	1.1	415
197	A lymphoproliferative disorder caused by human T-lymphotropic virus type I. <i>American Journal of Medicine</i> , 1987, 83, 953-958.	1.5	9
198	Complete nucleotide sequence of the AIDS virus, HTLV-III. <i>Nature</i> , 1985, 313, 277-284.	27.8	2,554

#	ARTICLE	IF	CITATIONS
199	A molecular clone of HTLV-III with biological activity. <i>Nature</i> , 1985, 316, 262-265.	27.8	391
200	Nucleotide sequence of transforming human c-sis cDNA clones with homology to platelet-derived growth factor. <i>Nucleic Acids Research</i> , 1985, 13, 5007-5018.	14.5	63
201	Transformation of NIH 3T3 cells by a human c-sis cDNA clone. <i>Nature</i> , 1984, 308, 464-467.	27.8	186
202	Evolution of Multiple Domains of the HIV-1 Envelope Glycoprotein during Coreceptor Switch with CCR5 Antagonist Therapy. <i>Microbiology Spectrum</i> , 0, , .	3.0	1